Administration of AS03B-adjuvanted A(H1N1)pdm09 vaccine in children aged <3 years enhances antibody response to H3 and B viruses following a single dose of trivalent vaccine one year later.

Administration of AS03B-adjuvanted A(H1N1)pdm09 vaccine in children aged <3 years enhances antibody response to H3 and B viruses following a single dose of trivalent vaccine one year later.

BACKGROUND: We report on a follow-up clinical and serological investigation of 274 children who received seasonal influenza vaccine (trivalent inactivated vaccine [TIV]) 1 year after receipt of either AS03(B)-adjuvanted subunit or whole virus monovalent A(H1N1)pdm09 vaccine and describe the antibody...

Full description

Bibliographic Details
Main Authors:	Hoschler, K, Andrews, N, Faust, SN, Finn, A, Pollard, A, Snape, M, Walker, W, Zambon, M, Miller, E
Format:	Journal article
Language:	English
Published:	2014

Similar Items

Effectiveness of the trivalent MF59 adjuvated influenza vaccine in preventing hospitalization due to influenza B and A(H1N1)pdm09 viruses in the elderly in Italy, 2017 – 2018 season
by: Antonino Bella, et al.
Published: (2019-06-01)

Seroprevalence of Influenza A(H1N1)pdm09 Virus Antibody, England, 2010 and 2011
by: Katja Hoschler, et al.
Published: (2012-11-01)

Preventive behaviours towards influenza A(H1N1)pdm09 and factors associated with the intention to take influenza A(H1N1)pdm09 vaccination
by: Cho Naing, et al.
Published: (2012-12-01)

Effectiveness of A(H1N1)pdm09 influenza vaccine in adults recommended for annual influenza vaccination.
by: Giedre Gefenaite, et al.
Published: (2013-01-01)

Safety of Influenza A H1N1pdm09 Vaccines: An Overview of Systematic Reviews
by: Lene Kristine Juvet, et al.
Published: (2021-10-01)

Repeated Influenza Vaccination Boosts and Maintains H1N1pdm09 Neuraminidase Antibody Titers
by: Lena Hansen, et al.
Published: (2021-10-01)

Evaluation of the potential effects of AS03-adjuvanted A(H1N1)pdm09 vaccine administration on the central nervous system of non-primed and A(H1N1)pdm09-primed cotton rats
by: Camille Planty, et al.
Published: (2017-01-01)

T-cell responses in children to internal influenza antigens, 1 year after immunization with pandemic H1N1 influenza vaccine, and response to revaccination with seasonal trivalent-inactivated influenza vaccine
by: Lambe, T, et al.
Published: (2012)

T-cell responses in children to internal influenza antigens, 1 year after immunization with pandemic H1N1 influenza vaccine, and response to revaccination with seasonal trivalent-inactivated influenza vaccine.
by: Lambe, T, et al.
Published: (2012)

Immunogenicity of Modern Vaccine Viruses of Influenza A (H1N1)pdm09 According to Graphical Analysis
by: V. S. Vakin, et al.
Published: (2017-10-01)

Differential Influence of Age on the Relationship between Genetic Mismatch and A(H1N1)pdm09 Vaccine Effectiveness
by: Lirong Cao, et al.
Published: (2021-04-01)

Effectiveness of MF59™ adjuvanted influenza A(H1N1)pdm09 vaccine in risk groups in the Netherlands.
by: Leonoor Wijnans, et al.
Published: (2013-01-01)

No Evidence for Disease History as a Risk Factor for Narcolepsy after A(H1N1)pdm09 Vaccination.
by: Favelle Lamb, et al.
Published: (2016-01-01)

Bell's palsy and influenza(H1N1)pdm09 containing vaccines: A self-controlled case series.
by: Leonoor Wijnans, et al.
Published: (2017-01-01)

Functional and Binding H1N1pdm09-Specific Antibody Responses in Occasionally and Repeatedly Vaccinated Healthcare Workers: A Five-Year Study (2009-2014)
by: Håkon Amdam, et al.
Published: (2021-12-01)

Influenza A(H1N1)pdm09 virus and asthma
by: Masatsugu eObuchi, et al.
Published: (2013-10-01)

Immune responses in pigs vaccinated with adjuvanted and non-adjuvanted A(H1N1)pdm/09 influenza vaccines used in human immunization programmes.
by: Eric A Lefevre, et al.
Published: (2012-01-01)

Pandemic influenza A(H1N1)pdm09 seroprevalence in Sweden before and after the pandemic and the vaccination campaign in 2009.
by: Andreas Mörner, et al.
Published: (2012-01-01)

Detection of influenza A, B and subtypes A (H1N1) pdm09, A (H3N2) viruses by multiple QRT-PCR in clinical samples
by: Pool Marcos, et al.
Published: (2017-06-01)

The 2015 influenza A (H1N1) pdm09 outbreak in India
by: Manoj Murhekar, et al.
Published: (2016-01-01)

Influenza A(H1N1)pdm09 and postpandemic influenza in Lithuania
by: Ambrozaitis Arvydas, et al.
Published: (2016-01-01)

Timelines of infection and transmission dynamics of H1N1pdm09 in swine.
by: Laetitia Canini, et al.
Published: (2020-07-01)

Assessing the Intense Influenza A(H1N1)pdm09 Epidemic and Vaccine Effectiveness in the Post-COVID Season in the Russian Federation
by: Anna Sominina, et al.
Published: (2023-08-01)

Efficiency of Points of Dispensing for Influenza A(H1N1)pdm09 Vaccination, Los Angeles County, California, USA, 2009
by: Shubhayu Saha, et al.
Published: (2014-04-01)

Usefulness of health registries when estimating vaccine effectiveness during the influenza A(H1N1)pdm09 pandemic in Norway
by: Guzmán Herrador Bernardo, et al.
Published: (2012-03-01)

Assessing Antigenic Drift of Seasonal Influenza A(H3N2) and A(H1N1)pdm09 Viruses.
by: Nipaporn Tewawong, et al.
Published: (2015-01-01)

ANTIVIRAL EFFECT OF «KAGOCEL» SUBSTANCE IN VITRO ON INFLUENZA VIRUSES H1N1, H1N1PDM09 AND H3N2
by: I. T. Fediakina, et al.
Published: (2019-06-01)

Profiling of humoral response to influenza A(H1N1)pdm09 infection and vaccination measured by a protein microarray in persons with and without history of seasonal vaccination.
by: Elisabeth G W Huijskens, et al.
Published: (2013-01-01)

H1N1 antibody persistence 1 year after immunization with an adjuvanted or whole-virion pandemic vaccine and immunogenicity and reactogenicity of subsequent seasonal influenza vaccine: a multicenter follow-on study.
by: Walker, W, et al.
Published: (2012)

Antigenic Drift of the Influenza A(H1N1)pdm09 Virus Neuraminidase Results in Reduced Effectiveness of A/California/7/2009 (H1N1pdm09)-Specific Antibodies
by: Jin Gao, et al.
Published: (2019-04-01)

Cell-Based Influenza A/H1N1pdm09 Vaccine Viruses Containing Chimeric Hemagglutinin with Improved Membrane Fusion Ability
by: Madoka Kawahara, et al.
Published: (2020-08-01)

Persistently high antibody responses after AS03-adjuvanted H1N1pdm09 vaccine: Dissecting the HA specific antibody response
by: Anders Madsen, et al.
Published: (2021-04-01)

Fatal Influenza A(H1N1)pdm09 Encephalopathy in Immunocompetent Man
by: Marie Simon, et al.
Published: (2013-06-01)

The hemagglutinin of the influenza A(H1N1)pdm09 is mutating towards stability
by: Castelán-Vega JA, et al.
Published: (2014-10-01)

Influenza A(H1N1)pdm09 Virus in Pigs, Réunion Island
by: Eric Cardinale, et al.
Published: (2012-10-01)

POPULATION IMMUNITY TO INFLUENZA VIRUS A(H1N1)pdm09, A(H3N2) AND B IN THE ADULT POPULATION OF THE RUSSIAN FEDERATION LONG-TERM RESEARCH RESULTS
by: O. S. Konshina, et al.
Published: (2017-03-01)

Pandemic (H1N1) 2009 Risk for Nurses after Trivalent Vaccination
by: Mark B. Loeb, et al.
Published: (2010-04-01)

Long-term follow-up in patients with HIV vaccinated with pandemic influenza A(H1N1)/09 AS03-adjuvanted split virion vaccine and seasonal trivalent influenza split virion vaccine
by: Karlis Pauksens
Published: (2013-08-01)

Safety and immunogenicity of AS03 B adjuvanted split virion versus non-adjuvanted whole virion H1N1 influenza vaccine in UK children aged 6 months-12 years: Open label, randomised, parallel group, multicentre study
by: Waddington, C, et al.
Published: (2010)

Safety and immunogenicity of AS03B adjuvanted split virion versus non-adjuvanted whole virion H1N1 influenza vaccine in UK children aged 6 months-12 years: open label, randomised, parallel group, multicentre study.
by: Waddington, C, et al.
Published: (2010)